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Abstract
Cholesterol plays a critical role in liposome composition. It has great impact on the behavior
of liposome in vitro and in vivo. In order to verify the possible effects from cholesterol charge,
surface shielding and chemical nature, two catalogs of liposomes with charged and PEGylated
cholesterols were synthesized. Anionic liposomes (AL) and cationic liposomes (CL) were
prepared, with charges from hemisuccinate and lysine in cholesterol derivatives, respectively.
Characteristics of different formulated liposomes were investigated after doxorubicin encapsulation, using neutral liposomes (NL) as control. Results showed that after PEGylation, AL
and CL liposomes displayed prolonged retention release profile, while kept similar size distribution, encapsulation efficiency, low cytotoxicity and hemolysis comparing with NL.
Confocal laser scanning microscopy and flow cytometry experiments confirmed the significantly higher cell uptake from AL and CL vesicles than the NL in mouse breast carcinoma and
melanoma cells, human epithelial carcinoma and hepatoma cells. It was in accordance with our
corresponding cellular mortality studies of DOX-loaded liposomes. The in vivo anti-tumor
effect experiments from charged liposomes also presented much higher tumor inhibition
effect (70% vs 45%, p < 0.05) than NL liposomes. This is the first time reporting anti-cancer
effect from charged cholesterol liposome with/without PEGylation. It may give deeper understanding on the liposome formulation which is critical for liposome associated drug research and development.
Key words: Liposome, Cholesterol derivative, charged, PEGylation, image, Drug delivery.

1. Introduction
Liposomes have been widely used in the therapeutic drug delivery, including small molecular
drugs, proteins, genes (DNA or RNA) and diagnostic
contrast reagents.[1-6] For example, the doxorubicin
encapsulated liposome (Doxil) has been approved by
FDA for ovarian cancer and Kaposi's sarcoma treatment in United States over 10 years.[7]
Although liposome has been successfully applied in the clinic, further efforts on the component
optimization are still a hot topic in the research for

satisfying requirements from clinic.[8-13] Changes of
the liposomes' characteristics, including size, composition, surface properties and charge, may attribute
for the application needed. In these factors, charge is
believed to be one of the key factors affecting cellular
adhesion/uptake and drug delivery.[14, 15] Normally, liposomes with cationic lipids are prone to binding
cells than liposomes with anionic lipids due to electrostatic interaction with negatively charged cell
membrane (sialic acids and phospholipid head
http://www.thno.org
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groups). This is the reason why cationic liposomes
were frequently used to improve in vitro and in vivo
efficacy for drug delivery.[9-11] However, once cationic liposomes were administrated into systemic circulation by intravenous injection, the effect from
blood clearance and reticuloendothelial system cannot be ignored.[16] Meanwhile, it has been reported
that negatively charged liposomes displayed faster
and greater endocytosis than neutral liposomes in
some cells.[17-20] To clarify this confusion, Dr. Dan
applied
Debye-Huckel
limit
of
the
Poisson–Boltzmann model to study the effect of liposome
charge on cellular adhesion. Results showed that this
liposome-cell interaction is determined not only from
the lipids charge in the liposome, but also from lipids
composition and cell types.[15]
PEGylated lipids can contribute longer circulation for liposome because of the “steric stabilization”
effect. With the surface hydrophilic protective layer
from PEG chain, PEGylated liposome showed characterizations of more stability, sustained release, prolonged blood circulation time and reduced mononuclear phagocyte system uptake. Although the supplementation of PEGylation into liposome can neutralize or reduce the net zeta potential of charged liposomes, the expected shielding effect in vivo was
greatly diversified. From Dr. Torchlin’s studies,
liposomes containing phosphatidic acid or phosphatidyl serine had the similar size and charge. After
PEGylation, it was found that only phosphatidic acid
containing vesicles could extended circulation time,
not phosphatidyl serine. There must be other factors
we are not clear to affect these biological
properties.[11]
Several studies have been reported that characterization of liposome composition, including charge
and PEGylation, may have a marked influence on the
in vitro and in vivo behavior of the carried chemotherapeutics. Besides phospholipids modification,
cholesterol is well-known to work as the framework
in liposomal membrane, which could reduce the fluidity stabilize the bilayer and control the drug permeability properties of liposomal membrane
bilayer.[7] In the previous cholesterol studies, most of
the researches were focused on the content effect; few
studies were conducted on the cholesterol itself and
its derivatives on the behavior of liposome so far, especially for the cholesterol charges. This critical effect
factor from charged cholesterol and surface shielding
on liposomal behavior are deserved to be explored.
Thus, in order to clarify this hypothesis, in this
study, three types of cholesterol derivatives, including
cholesterol hemisuccinate (CHEMS) with negative
charge, lysine-based cholesterol (CHLYS) with posi-
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tive charge and PEGylated cholesterol (Chol-PEG)
without charge were synthesized. These three types of
cholesterols were incorporated with phospholipids to
form liposome with according surface charge. Currently, imaging techniques or modalities have been
incorporated into drug delivery system, especially in
the nanomedicine field.[21-25] Comparing with traditional analysis, high resolution images can not only
provide quick and accurate information of drug behaviors or new materials in the period of treatment,
but also has close relationship with drug efficacy
which can be called as theranostics. It can facilitate the
localization and quantization of radioisotope or optical probe labeled materials in drug delivery study and
clinic for early diagnosis and personal medicine.[26]
In our study, with the assistance from fluorescent
imaging and other classic assays, Doxorubicin (DOX),
which has therapeutic effect with strong fluorescence
to nucleus staining, was also designed to loaded into
this three cholesterol sourced cationic, anionic and
neutral liposomes with/without PEGylation to compare the behavior in vitro and in vivo.

2. Materials and Methods
2.1. Materials
L-α-phosphatidylcholine (egg hydrogenated,
HEPC, 99% deacetylated degree) was purchased from
Q. P. Corporation Fine Chemical Division (Tokyo,
Japan). Doxorubicin hydrochloride (DOX), cholesterol
(Chol), methoxypoly(ethylene glycol) (mPEG, MW=
2000 Da) and dicyclohexylcarbodiimide (DCC) were
purchased from Sigma-Aldrich Chemical Co. (USA).
Boc-protected (Boc tert-butoxycarbonyl) lysine was
purchased from Chengdu New Technology Company
Limited (Chengdu, China). Three cholesterol derivatives (CHLYS, CHEMS and Chol-PEG) were synthesized in our group. The mouse breast carcinoma 4T1
cells, mouse melanoma B16F10 cells, human epithelial
carcinoma Hela cells and human hepatoma HepG2
cells were purchased from Shanghai Institute of Biochemistry and Cell Biology (Chinese Academy of
Sciences,
Shanghai,
China).
3-(4,
5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium
bromide (MTT) was purchased from Sigma (St. Louis,
MO, USA). Cell culture media (RPMI 1640), fetal bovine serum (FBS), trypsin, and antibiotics were purchased from Gibco BRL (USA). All the other chemicals
of analytical grade were purchased from local commercial suppliers.

2.2. Synthesis of cholesterol derivatives
2.2.1 Synthesis of lysine-based cholesterol (CHLYS)
Synthesis of CHLYS was performed according to
http://www.thno.org
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our previous work with some modifications.[27] In
brief, a solution of dicyclohexylcarbodiimide (DCC,
0.82 g, 4 mmol) in anhydrous dichloromethane
(CH2Cl2, 20 mL) was added dropwise to a mixed solution of cholesterol (1.16 g, 3 mmol), Boc-protected
lysine
(0.69
g,
2
mmol)
and
a
few
4-dimethylaminopyridine (DMAP) in anhydrous
CH2Cl2 (20 mL). The mixed solution was stirred for 2
h at 0oC overnight at room temperature. The white
precipitation of dicyclohexylurea (DCU) was removed by filtration. Obtained filtrate was condensed
and purified by flash chromatography on silica gel
(CH2Cl2/MeOH 85:15, with trace TEA, Rf= 0.15) to get
CHLYS-Boc. Trifluoroacetic acid (1 mL) was dropwise
added to a solution of CHLYS-Boc (0.1 mmol) in anhydrous CH2Cl2 (1 mL) at 0oC for Boc group detachment. After 2 h stirring at room temperature, product
was concentrated and recrystallized in anhydrous
diethyl ether, with yield of 0.36 g (71%). IR
γ/cm−1:1738 (ester, C=O); 1HNMR (CDCl3, δ ppm):
0.68 (s, 3H, H-18), 0.91 (s, 3H, H-21), 2.29 (d, 2H, H-4),
3.11 (m, 2H, -CH2), 4.22 (m, 1H, -CH2-NH), 4.65 (m,
1H, -CH), 5.08 (d, 2H, -CH2-NH), 5.38 (t, 1H, H-6).
(Supplementary Material: Figure S1 A)

2.2.2 Synthesis of cholesterol hemisuccinate (CHEMS)
Succinic anhydride (3.6 g, 36.0 mmol) was added
to a solution of cholesterol (5.0 g, 12.9 mmol) in anhydrous pyridine (40 mL). The reaction mixture was
refluxed at 90 oC under nitrogen for 24 h. The residue
was washed with HCl/distilled ice water (5:95, v/v).
CHEMS can be obtained by recrystallized from acetone and dried under vacuum with yield of 5.3 g,
(85%); mp 185oC. IR γ/cm−1: 1734 (ester, C=O); 1H
NMR (CDCl3, δ ppm): 0.67 (s, 3H, H-18), 0.91 (s, 3H,
H-21), 2.32 (d, 2H, H-4), 2.60 (m, 2H, -COCH2), 2.68
(m, 2H, -CH2CO), 5.36 (t, 1H, H-6). (Supplementary
Material: Figure S1 B)

2.2.3 Synthesis of CHEMS-PEG
According to the protocol,[28] sulfonyl chloride
(0.67 g, 5 mmol) was added to a solution of CHEMS
(2.4 g, 5 mmol) in 30 mL of anhydrous CH2Cl2 with 5 h
refluxing under nitrogen stream. mPEG2000 (2 g, 1
mmol) was added and the reaction was continued for
another 5 h. At the end, the reaction mixture was
condensed, and precipitated in diethyl ether thrice,
recrystallized in anhydrous ethanol thrice and dried
under vacuum. Dialysis was used to remove excessive
mPEG (10 kDa cut-off), with yield of 2.2 g (88%). IR
γ/cm−1: 1734 (ester, C=O); 1HNMR (CDCl3, δ ppm):
0.68 (s, 3H, H-18), 0.90 (s, 3H, H-21), 2.33 (d, 2H, H-4),
2.60 (m, 2H, -COCH2), 2.66 (m, 2H, -CH2CO), 3.37 (s,
3H, -CH3), 3.64 (m, 176H, -OCH2O), 5.36 (t, 1H, H-6).
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(Supplementary Material: Figure S1 C)

2.3. Preparation of various charged liposomes
and drug loading
Liposomes were prepared by traditional thin
film-hydration method with different composition of
HEPC, Chol, Chol-PEG and different charged components (CHLYS and CHEMS), respectively. Loading
DOX into the liposomes was carried out by the remote
loading method with an ammonium sulfate
gradient.[29, 30] Briefly, different composition lipids
were dissolved in 20 mL of chloroform/methanol (3:1,
v/v), dried into thin film by rotary evaporator and
hydrated in 10 mL of 120 mM of ammonium sulfate
solution. The mixture was further treated using a
probe sonicator (UCX 130PB, sonics & materials INC.,
USA) for 2 min at 50 W. Unloaded ammonium sulfate
was removed through dialysis against 0.9% NaCl (10
kDa cut-off). DOX solution was added to the liposomal dispersion with drug-to-lipid ratio of 1/10 (w/w)
and incubated at 60oC for 2 h. Commonly, the liposome formulations were stored at 4oC, and extruded
through 0.22- micron filter for sterilization before use.

2.4. Size distribution, morphology and zeta
potential
The particle size distribution and surface charge
of liposomes (0.5 mg/mL) in phosphate-buffered saline (PBS, pH 7.4) were measured by dynamic laser-light scattering (DLS) by Zetasizer (Nano ZS,
Malvern Instruments Ltd., UK). Liposomes were
placed on copper grid films and stained with 2%
(w/v) phosphotungstic acid for morphological observation by transmission electron microscopy (TEM)
(JEM-100CX , JEOL, Japan), while dropped on silica
slices for scanning electron microscopy (SEM) (Hitachi S4800, Japan) review. Surface properties of the
liposomes were observed by atomic force microscopy
(AFM) (MFP-3D, Asylum Research, USA) on mica
slices.

2.5. Drug entrapment efficiency
Untrapped free DOX was separated from liposomes by size exclusion chromatography (SEC) using
a Sephadex G-75 column (GE Healthcare, Uppsala,
Sweden) with UV detection at 480 nm. Liposomes
were collected and dissolved in 10% Triton X-100 for
the content measurement of DOX in the liposomes by
UV-vis spectrophotometry (Lambda 650, Perkin
Elmer, USA). The loading/entrapment efficiency was
calculated by
Entrapment efficiency (%)= (encapsulated drug
in liposomes / amount of total drug) × 100%.

http://www.thno.org
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2.6. In vitro DOX release from liposomes
oC

Release studies were performed at 37
in PBS
buffer (pH 7.4). Liposomes with a final DOX concentration of 0.5 mg/mL were added into a dialysis tube
(10 kDa cut-off), and stirred in PBS medium at 37 oC
under perfect sink conditions. At predetermined time
intervals, 1 mL of the medium was taken out for concentration detection by UV-vis spectrophotometry.
Same volume of fresh media was fulfilled.

2.7. Cytotoxicity study
Cytotoxicity was determined by classic MTT assay. Briefly, 4T1 cells were seeded in 96-well plate at
concentration of 5 × 103 cells/well in 1640 medium
and cultured overnight. Drug-free liposome formulations with/without 5 mol% Chol-PEG were added to
reach a final concentration of 200 μg/mL, and incubated for 24 h. Measurement was performed in microplate reader (Model 550, Bio-Rad, USA).

2.8. Hemolysis assay
Hemolytic activity was evaluated by determining hemoglobin release from erythrocyte after incubation with different drug-free liposome formulations
(cationic, anionic and neutral ones with/without 5
mol% Chol-PEG). Briefly, rabbit blood samples were
harvested from arteria auricularis into test tubes containing 124 mM sodium citrate (sodium citrate:
blood= 1: 9, v/v), centrifuged and washed with saline.
The obtained red blood cells (RBC, 1 mL) were diluted
with saline to 10 mL. 0.5 mL of the RBC suspension
was incubated with 2 mL of liposomes (2.5 mg/mL) at
37oC with gentle shaking. After 1 h, the samples were
centrifuged at 3000 rpm for 5 min. The absorbance (A)
of the supernatant was measured by UV-vis spectrophotometry at 545 nm. A negative control was prepared by mixing 0.5 mL of the RBC suspension with 2
mL of saline (0% lysis), using water as a positive control (100% lysis). The absorbance value of positive
should be 0.8 ± 0.3, while negative one should be less
than 0.03.[31] The hemolytic rates of the samples were
calculated as the following equation (Eq. 1):
Hemolytic rate (%)= [(At-Anc)/ (Apc-Anc)] × 100%
…(1)
where At represents absorbance value of test sample,
Anc and Apc stand for absorption value of negative and
positive controls, respectively.

2.9. Cellular uptake of DOX-loaded PEGylated
liposomes
Cellular uptake was examined by confocal laser
scanning microscopy (CLSM, TCP SP5, Leica, Germany) and flow cytometry (Cytomics FC500, Beck-

man Coulter).Various carcinoma cells including 4T1,
B16F10, Hela and HepG2 were seeded on a 35 × 12
mm cell culture dish (NEST Biotech Co., LTD, China)
for CLSM view, or on 6-well plate for flow cytometry
measurement with cell population of 1 × 106 cells.
Drug-loaded PEGylated liposomes were added and
incubated for 0.5, 1 and 2 h at final DOX concentration
of 5 μg/mL. Cells were rinsed thrice with ice-cold PBS
and observed by CLSM with excitation/emission at
488/590 nm. In addition, cells were trypsinized and
resuspended in 0.5 mL PBS buffer for fluorescence-activated cell sorting (FACS). At least 1×105
gated events per sample were collected.

2.10. In vitro therapeutic test
The cellular mortality study of DOX-loaded liposomes was performed against 4T1 cells on 96-well
plate. Cells were exposed to different liposome formulations at a final DOX concentration of 5 μg/mL
for 6, 12, 24, 36 and 48h, respectively. The viability
was detected by MTT assay using DOX solution as
control.

2.11. In vivo anti-tumor activity
BALB/c mice (male, 18-22 g) were purchased
from West China Experimental Animal Center of Sichuan University (China). They were maintained in a
germ-free environment and allowed free access to
food and water. All animal experiments were agreed
to requirement from our IACUC and NIH guidelines
for care and use of research animals. 5 × 105 4T1 cells
in 50 μl sterile PBS was embedded at the left flank of
BALB/c mice by subcutaneous injection. After the
volume of inoculated tumor reached approximately
100 mm3, mice were divided into 6 groups randomly
(6 mice per group), and received different formulations along with controls via tail vein injection at a
dose of 5 mg DOX/kg body weight on the 0, 4th, 8th
and 12th day, respectively. The transition of tumor
volume and body weight was measured every three
days thereafter. Tumor volume was calculated using
Eq. (2) given below:
V [mm3]= 1/2 × LW2

…(2)

Where, L and W stand for the lengths in long and
short directions of the tumors, respectively. On the
21st days, all mice were sacrificed. Tumor inhibition
rates were calculated according to Eq. (3) as follows:
Tumor Inhibition Rate (TIR, %)= [(Wc- Wt)/Wc] ×
100%
…(3)
Here Wc referred to the average weight of tumor in
control group; Wt referred to average weight of tumor
in treated group.
An autopsy was performed and specimens of
http://www.thno.org
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heart were collected for microscopic examination.
Samples were fixed in 4% neutral buffered formaldehyde and embedded in paraffin. 5 μm thick sections
were placed on polylysine-coated slides and stained
with hematoxylin and eosin (H&E). The stained slides
were pictured under microscope (BX60, Olympus,
Japan) at 200 × magnifications.

3. Results and discussion
3.1. Characterization of liposomes
Non-PEGylated liposomes, as well as PEGylated
anionic liposomes (AL), cationic liposomes (CL) and
neutral liposomes (NL) were prepared with according
characterization in size distribution and zeta potential
(Table 1). After incorporating 5 mol% of PEGylated
component, all liposomes displayed narrower size
distribution (all around 100 nm) than conventional
non-PEGylated ones. The parameters of phosphalipids sources, ratio and charge can only influence
the average size in a limited level. The images of SEM,
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AFM and TEM images (Figure 1A, B and C) showed
that PEGylated AL liposomes (with or without DOX)
was in spherical shape, and the encapsulation process
did not affect the size and zeta potential. Similar results were obtained from DLS measurement (Table 1).
Particles aggregation can be observed in
non-PEGylated liposomes after one day’s storage at
4oC, which cannot be found for PEGylated liposomes.
As expected, zeta potential has close relationship
with the charge on the cholesterol derivatives. Liposomes prepared from HEPC/Chol (70/30, mol/mol)
were neutral (-2.0 mV). While adding 15 mol%
CHLYS or CHEMS, zeta potential changed to +37.2
mV or -33.5 mV, respectively (Table 1). Introduction
of PEG to charged liposomes reduced the absolute
value of surface charges (from +37.2 mV to +15.2 mV,
or from -33.5 mV to -14.6 mV, respectively). No significant change was found in the conventional neutral
liposomes, which was consistent with previous research on the shielding effect of PEG.[32]

Figure 1. The typical patterns of drug-free or DOX-loaded PEGylated anionic liposome (AL). (A) SEM image of drug-free AL. (B) Three dimensions AFM image of drug-free AL. (C) TEM image of DOX-loaded AL (bar= 200 nm). (D) The DOX release profiles from different charged
DOX-loaded PEGylated liposomes (n= 3). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome, AL: PEGylated anionic liposome,
DOX: free DOX).

http://www.thno.org
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Table 1. Composition, size distribution and zeta potential of liposomes.
Liposome type *

Molar radio

Particle size (nm)
91.5†

Zeta potential (mV)

Entrapment efficiency (%)

HEPC/CHOL

70:30

151.3±

-2.0± 4.4

95.3± 4.7

HEPC/CHOL/CHLYS

70:15:15

163.1± 101.6†

37.2± 6.2

96.7±4.5

HEPC/CHOL/CHEMS

70:15:15

144.7± 95.1†

-33.5± 5.4

95.8±5.0

HEPC/CHOL/CHEMS-PEG (NL)

65:30:5

108.2 ± 34.2

-2.3 ± 4.4

96.6±3.9

HEPC/CHOL/CHLYS/CHEMS-PEG (CL)

65:15:15:5

104.5 ±40.1

15.2 ± 5.8

97.3±4.8

HEPC/CHOL/CHEMS/CHEMS-PEG (AL)

65:15:15:5

106.1 ±39.8

-14.6 ± 5.1

98.2±3.1

*NL:

PEGylated neutral liposome, CL: PEGylated cationic liposome, and AL: PEGylated anionic liposome.
† The size distribution is abroad.

3.2. Drug entrapment and in vitro DOX release from liposomes
It was demonstrated that remote loading method
could efficiently encapsulate DOX into liposomes, in
which ammonium sulfate gradient existed. The higher
intra-liposomal concentration of (NH4)2SO4 than that
of the medium was used as the driving force for the
influx of amphipathic weak bases, such as DOX.[29]
In the presence of SO42-, a gel-like precipitate of DOX
could form and be trapped inside the liposomes. Size
exclusion chromatography was used to separate free
DOX from DOX-loaded liposome suspension. As
shown in the UV elution profile (Supplementary Material: Figure S2), the small molecule of free DOX was
eluted from 100 to 120 mL, while liposomes with diameter of 100 nm were first eluted from 7.0 to 9.5 mL.
The experiments also showed that there were no significant differences in drug entrapment efficiency
among the formulations (charged and neutral, with
PEG or not). All the entrapment efficiency were as
high as 95% (drug/lipid= 1:10, w/w) (Table 1), which
means the surface charge and PEGylation had negligible impact on DOX loading efficiency. These results
are consistent with previous findings.[30] Additionally, the PEGylated DOX-loaded liposomes can keep
colloidal stable form for 3 months when stored at 4oC
without any drug leakage.
Drug release profiles studies were also performed (Figure 1D). Compared with 4 h complete
release of free DOX, the release profiles of PEGylated
liposomes were obviously delayed post 48th h due to
encapsulation induced retaining effect of DOX. Interestingly, neutral liposomes (NL) showed a more rapid
release at 48th h time point, while the release in both
cationic (CL) and anionic (AL) liposomes formulation
started at 60th h point, and reached 70~ 80% accumulated release at 72nd h. The possible mechanism is
that DOX entrapped by gradient ammonium sulfate
may exhibit biphasic release, including slow dissolution of precipitate and membrane diffusion.[33] The
drug release behavior was firstly governed by the
slow precipitate dissolution rate inside liposomes,

which led to the sustained release for a long period of
time.[34] And then the dissolved drug could diffuse
from the lipid membrane. During the test, precipitation in dialysis tube was observed in neutral vesicles
from about 72nd h (data not shown), resulting in the
incomplete release of DOX. Nevertheless, charged
liposomes (AL and CL) displayed more stable for
their mutual repulsive force in the suspension system.
It was assumed that after 60th h, cationic or anionic
lipid membrane might have some structure defects
due to higher electrostatic interactions on membrane
permeability,[35] thus accelerating membrane diffusion and leading to complete DOX release.

3.3. Cytotoxicity study
Various drug-free liposomes with/without
PEGylation showed significant difference in cytotoxicity (Figure 2A). Without PEGylation, AL group presented much higher cellular viability (about 87%) than
that of CL group (around 60%, p < 0.05). While after
PEGylation, all charged liposomes showed negligible
toxicity on 4T1 cells, remaining more than 90% viability. It is consistent with the previous test on cationic
vesicles.[14]

3.4. Hemolysis assay
Hemolysis study was performed to investigate
the potential toxicity after the intravenous injection of
PEGylated AL, CL and NL in vivo. The leakage of
hemoglobin was used to quantitatively compare the
membrane-damaging properties of these liposomes.
As shown in Figure 2B, the conventional
non-PEGylated liposomes without PEG showed much
higher extents of hemolysis rate than the PEGylated
liposomes at 2 mg/mL concentration (p < 0.05).
Without 5% CHEMS-PEG, NL and AL induced mild
hemolysis (~17%) while cationic liposomes showed
~55% hemolysis rate due to the serious destroys to red
blood cell. These results were consistent with the
study from Lam’s group on different charged micelles.[36] It was also supported by several previous
investigations, which indicated that the primary
amines (positive charge) on the surface of materihttp://www.thno.org
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als/particles may induce hemolysis.[37] On the contrary, the hemolysis rates in all PEGylated liposomes
were less than 5%. It is known that, PEG is a highly
hydrated polymer and has a high degree of segmental
flexibility in aqueous solution. Thus, PEGylation is
commonly considered to reduce the serious cellular
interaction,[38, 39] and consequently reduce the
damage to red blood cell. With the improved the biocompatibility, the PEGylated liposomes could be
further explored for anti-tumor activity, cellular uptake and in vivo effect.

3.5. Cellular uptake of DOX-loaded PEGylated
liposomes
Cellular uptake of liposomes was studied via
confocal microscopy (Figure 3A) and flow cytometry
analysis (Figure 3B). DOX showed the fastest cellular
uptake and could be used for cell nucleus model because of its property of fluorescent and therapy. Figure 3A showed AL treated cells presented approximately the same fluorescence intensity as cells in CL
group on 4T1 cells, which was much higher than that
of NL at 2 h post-treatment. In addition, AL treated
cells also showed the highest fluorescence intensity in
all liposome formulations in Hela, HepG2 and B16
cells.
There were no obvious effects from the original
size, morphology, cytotoxicity, encapsulation, release
and hemolysis for PEGylated cationic and anionic
liposomes, thus, the good cellular uptake of CL was
likely determined by the positive charges that could
induce electrostatic interaction with negatively
charged cell membrane as previously reported.[40]
Whereas observations with AL might be explained by
Dan’s research,[15] who found cell-liposome adhesion
depends not only on liposome charge, but also on the
cell type and specific endocytosis. Only when the

1098
cell-to-liposome charge ratio (either positive or negative) reaches the appropriate range for a specific cell
type would facilitate the liposome uptake.[17] These
phenomena were in accordance with previous research that negatively charged nanoparticles exhibited greater attraction to the macrophage and some
tumor cells.[36, 41, 42] It might be due to distinct cell
surface properties and specific endocytosis, since
specific protein corona will form on the surface of
liposomes after incubation with the cell medium.[43]
Moreover, the quick release of DOX in the formulation with CHEMS might also contribute to the higher
fluorescence intensity in AL group.[44] The detailed
mechanisms involved are unclear, which required
further investigation. The FACS data displayed the
similar results and they have high consistent with
results from confocal images (Figure 3B).

3.6. In vitro cellular mortality
In vitro anti-tumor activities of DOX-loaded
PEGylated liposomes were evaluated via the determination of cell mortality on 4T1 tumor cells at 6th,
12th, 24th, 36th and 48th h time point (Figure 4). Free
DOX showed the highest cellular mortality at each
time point, charged liposomes (CL and AL) showed
slightly lower anti-tumor proliferation, and the rate of
NL was the lowest one among all formulations. For
example, at 24th h of incubation time point, cell viability was about 30% for free DOX, AL and CL had
approximately 43% of survived cells, and NL-treated
group showed the highest cell viability of about 56%
(p < 0.05). This was in accordance with cellular uptake
experiment that charged liposomes had lower entrance than free DOX, but a greater extent of endocytosis than neutral ones.

Figure 2. Cytotoxicity of drug-free liposome with or without 5 mol% Chol-PEG (n= 3). (A) Cell viability of 4T1 cells after incubation with
drug-free liposome suspension (200 μg/mL). (B) Hemolysis rate of DOX-loaded liposome suspension (2 mg/mL) (NL: PEGylated neutral liposome,
CL: PEGylated cationic liposome and AL: PEGylated anionic liposome).
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Figure 3. Confocal microscopic images and flow cytometry results of various cells (4T1, Hela, HepG2 and B16F10) after incubation with free
DOX or DOX-loaded PEGylated liposomes at 37 °C for 2 h. (A) Confocal microscopic images (All the images were taken at the same fluorescence intensity. bar= 25 μm) (B) Flow cytometry results. (Excitation: 488 nm; emission: 590 nm).
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Figure. 4. Cell viability of 4T1 cells after incubation with free DOX or DOX-loaded PEGylated liposomes at a final DOX concentration of 5
μg/mL in various incubation time (n= 5). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome and AL: PEGylated anionic liposome).

3.7. In vivo anti-tumor activity
In vivo anti-tumor activities of DOX-loaded
PEGylated liposomes were tested using 4T1 breast
cancer tumor-bearing BALB/c mice at a dose of 5 mg
DOX/kg body weight. The change in the tumor
volume was measured continuously during the experiment (Figure 5A) and the tumor inhibition rates
were compared by tumor weight after all mice were
sacrificed (Figure 5B). The direct observation of tumors excised from 4T1-bearing mice was also considered for evaluation. For the ease of graphical representation, representative three tumors were shown in
Figure 5C. CL and AL treated groups showed high
tumor growth suppression with 70.9% and 68.2% (**p
> 0.05, CL group vs AL group), respectively. Meanwhile NL and free DOX displayed less tumor inhibitory effect with inhibition rate of 46.2% and 41.0%,
respectively. Different from the inhibition results in
vitro, DOX encapsulated in AL and CL showed improved effect than free DOX in vivo (*p < 0.05 vs DOX
group).
Although free DOX showed good cellular uptake, it was difficult to reach the tumor target site due
to the rapid clearance by opsonization and uptake by
the reticuloendothelial system.[45] Whereas DOX
loaded liposomes could be delivered to the tumor site
via enhanced permeability and retention effect. It was
reported that cationic liposomes could induce significant tumor growth suppression than neutral vesicles
and free drug, for preferential tumor accumulation.[9]
In our study, the anti-tumor effect of PEGylated anionic liposomes was comparable to cationic ones in
vivo. It might cause by the tumor cell type or the specific structure of CHEMS. In 4T1 cells, CL and AL
showed similar uptake, indicating 4T1 cells prefer
both cationic and anionic liposomes. As reported by

Hafez et al.,[35] CHEMS exhibited pH sensitive polymorphism, that when pH decreased to 5.5, CHEMS
induced changes in the bilayer forming cylinder of
liposome to the inverted hexagonal phase, thus accelerating drug release.
Significant toxicity was observed in the group
only administrated with DOX. In the DOX group, ~
20% of body weight was found to lose in mice and
displayed obvious no vigorousness in mice comparing with controls after the 3rd and 4th i.v. injection,
which reflected the signs of systemic toxicity from
DOX (Supplementary Material: Figure S3, *p < 0.05 vs
control and other liposome group). While mice treated with DOX-loaded liposomes showed none of these
adverse effects (p > 0.05), indicating the low acute
toxicity from the liposome formulation.
Considering the reported damage by free DOX
to heart, such as swollen cardiac muscle fibers, interstitial edema and inflammatory infiltration,[46-48]
histopathological investigation was conducted (Figure 5D). From the pathological data, no apparent
changes were observed in drug-free or DOX-loaded
liposome treatment groups. Thus, DOX-loaded
PEGylated liposomes showed less cardiac toxicity in
vivo as compared to free DOX.
Nowadays, research into the rational delivery
and targeting of pharmaceutical, therapeutic, and
diagnostic agents is at the forefront of projects in nanomedicine. These diagnostics based nanoparticles
can improve the sensitivity and specificity and help
identify abnormalities that cannot be detected with
traditional ways, provide more effective and/ or more
convenient routes of administration, lower therapeutic toxicity, extend the product life cycle, and ultimately reduce health-care costs. In the past few years,
a number of nanoparticle-based therapeutic and diagnostic agents have been developed for the treathttp://www.thno.org
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ment of cancer, diabetes, pain, asthma, allergy, and
infections. As a complicated therapeutic delivery
system, liposome is also one of the most successful
nanoparticles in the market approved by FDA for the
chemotherapeutic drug DOX loading and delivery.
Liposome allows passive targeted delivery and controlled release. With the assistance from diagnostic
reagent or the fluorescence form the capsulated drug
itself, liposome may be entity for drug delivery and
medical imaging, which fit the property of nanomedicine with diagnostic functionality referred by the
National Institutes of Health (NIH). The in vivo behavior of liposomes can be influenced by multiple
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interdependent factors. A minor change in chemical
formulation may result in evident diversification in
biological behavior.[33] To elucidate major factors
that affect anti-tumor activity of CL and AL, further in
vivo biodistribution behavior including tumor localization and elimination need to be proceeded, which
means the studies on physiological based pharmacokinetic (PBPK). DOX-loaded PEGylated charged liposomes exhibited strong anti-tumor efficiency both in
vitro and in vivo, indicating that using cholesterol derivatives might be a promising approach in forming
multi-functional liposomes for clinic.

Figure 5. In vivo anti-tumor activity of liposomes after i.v. injection of different DOX-loaded PEGylated liposomes with a DOX concentration of
5 mg/kg body weight (n=6). (A) The tumor volume in different treatment groups. (* p < 0.05 vs control group) (B) Tumor inhibition rates of
various formulations. (* p < 0.05 vs DOX group, ** p > 0.05) (C) The tumor morphology after three weeks treatment of different DOX preparation. (D) Mouse myocardium: treated with free DOX or DOX-loaded liposomes at a DOX concentration of 5 mg/kg body weight (H&E stain
200×). (NL: PEGylated neutral liposome, CL: PEGylated cationic liposome and AL: PEGylated anionic liposome).
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4. Conclusion
In our work, doxorubicin with property of fluorescence and therapy was successfully encapsulated
into charged liposome formulations from cationic and
anionic cholesterol derivatives. Such liposome formulations can serve as a model platform to further
study the in vitro and in vivo behavior with assistance
from fluorescent images, FACS technique and some
other classic methods. Our research demonstrated
that the charged liposomes incorporating with PEG
showed prolonged and improved release profile of
DOX, as well as low cytotoxicity and hemolysis. In
addition, charged liposomes, especially the anionic
ones have significant enhancement on uptake and cell
inhibition in various carcinoma cells than neutral
ones. In vivo tumor inhibition further confirmed that
charged liposomes had greater tumor inhibitory effect, indicating both positively and negatively
charged PEGylated liposome formulations with
modified cholesterol derivatives may be potential
drug carriers to improve the therapeutic efficacy.

Supplementary Material
Fig.S1 - S3. http://www.thno.org/v02p1092s1.pdf
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